Gufic Biosciences Limited (IN:GUFICBIO)
:GUFICBIO
GUFICBIO Stock Chart & Stats
₹338.15
-₹9.05(-1.92%)
At close: 4:00 PM EST
₹338.15
-₹9.05(-1.92%)
Day’s Range― - ―
52-Week Range₹267.50 - ₹409.00
Previous CloseN/A
Volume28.80K
Average Volume (3M)2.36K
Market Cap
₹30.21B
Enterprise Value₹33.13B
Total Cash (Recent Filing)₹880.79M
Total Debt (Recent Filing)₹3.69B
Price to Earnings (P/E)67.8
Beta0.77
Next Earnings
May 29, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend Yield0.03%
Share Statistics
EPS (TTM)1.24
Shares Outstanding100,282,510
10 Day Avg. Volume2,111
30 Day Avg. Volume2,356
Financial Highlights & Ratios
PEG Ratio-2.39
Price to Book (P/B)5.63
Price to Sales (P/S)4.13
P/FCF Ratio124.94
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Consistent Revenue GrowthSustained top-line expansion over multiple years indicates durable demand for the company’s formulations and supports capacity utilization and scale benefits. Long-term revenue growth underpins reinvestment, R&D, and margin stability if the company maintains product mix and market access.
Strong Gross And EBIT MarginsHealthy gross and EBIT margins reflect operational efficiency and pricing power in core product lines. Sustained margin levels provide buffer against raw material inflation and support funding for strategic initiatives, improving the company’s ability to withstand cyclical pressures.
Parenteral (injectable) Manufacturing CapabilitySpecialized injectable (parenteral) capability represents a structural competitive advantage because injectables require complex manufacturing, higher compliance, and typically earn better realizations. This supports premium contracts, export opportunities, and third-party manufacturing demand long term.
Bears Say
Inconsistent Free Cash FlowVolatile free cash flow undermines reliable internal funding for capex, working capital and debt repayment. Over a multi-month horizon, inconsistent cash conversion increases refinancing and liquidity risk, and may force reliance on external financing during expansion or regulatory-driven investments.
Moderately High Debt-to-equityElevated leverage raises interest and refinancing exposure, reducing financial flexibility to invest in capacity or pursue exports. In a sector requiring continual compliance and capex, higher debt can strain cash flows and limit ability to fund strategic growth without raising costs or diluting equity.
Volatile Net Income And EPS DeclineSharp EPS decline and net income volatility erode predictability of earnings power and free cash flow. This complicates long-term planning, reduces the capacity to self-fund growth or deleverage, and raises execution risk for sustained margin improvement and investment in higher-value therapies.
Gufic Biosciences Limited News
GUFICBIO FAQ
What was Gufic Biosciences Limited’s price range in the past 12 months?
Gufic Biosciences Limited lowest stock price was ₹267.50 and its highest was ₹409.00 in the past 12 months.
What is Gufic Biosciences Limited’s market cap?
Gufic Biosciences Limited’s market cap is ₹30.21B.
When is Gufic Biosciences Limited’s upcoming earnings report date?
Gufic Biosciences Limited’s upcoming earnings report date is May 29, 2026 which is in 46 days.
How were Gufic Biosciences Limited’s earnings last quarter?
Gufic Biosciences Limited released its earnings results on Feb 13, 2026. The company reported ₹1.239 earnings per share for the quarter, beating the consensus estimate of N/A by ₹1.239.
Is Gufic Biosciences Limited overvalued?
According to Wall Street analysts Gufic Biosciences Limited’s price is currently Overvalued.
Does Gufic Biosciences Limited pay dividends?
Gufic Biosciences Limited pays a Annually dividend of ₹0.1 which represents an annual dividend yield of 0.03%. See more information on Gufic Biosciences Limited dividends here
What is Gufic Biosciences Limited’s EPS estimate?
Gufic Biosciences Limited’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Gufic Biosciences Limited have?
Gufic Biosciences Limited has 100,282,510 shares outstanding.
What happened to Gufic Biosciences Limited’s price movement after its last earnings report?
Gufic Biosciences Limited reported an EPS of ₹1.239 in its last earnings report, beating expectations of N/A. Following the earnings report the stock price went down -2.022%.
Which hedge fund is a major shareholder of Gufic Biosciences Limited?
Currently, no hedge funds are holding shares in IN:GUFICBIO
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Gufic Biosciences Limited
Gufic Biosciences Limited engages in manufacture and marketing of active pharmaceutical ingredients (APIs), generic pharmaceuticals, and related services in India. It manufactures APIs and bulk drugs, such as antifungals, anesthetics, immuno suppressants, and intermediates for antifungals. The company also manufactures lyophilized injections, which include antibiotic, antifungal, cardiac, infertility, antiviral, and proton-pump inhibitor segments. In addition, it offers spark, criti care, and ferticare pharmaceutical products; and herbal and personal care products. The company supplies its products to hospital chains and medical facilities. It also exports its products to more than 20 countries. The company was founded in 1970 and is based in Mumbai, India.
Technical Analysis
Hikal Limited
―
Indoco Remedies Limited
―
IOL Chemicals & Pharmaceuticals Ltd.
―
Morepen Laboratories Limited
―
Orchid Pharma Limited
―